Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2009 (2009), Article ID 165637, 10 pages
Research Article

Characterization of Multidrug Resistant ESBL-Producing Escherichia coli Isolates from Hospitals in Malaysia

1Microbiology Division, Institute of Biological Science, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia
2Specialized Diagnostic Centre, Institute of Medical Research, Jalan Pahang, 50588 Kuala Lumpur, Malaysia
3Faculty of Agriculture and Biotechnology, Darul Iman University, Malaysia, 20400 Kuala Terengganu, Malaysia
4Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 11 February 2009; Accepted 11 June 2009

Academic Editor: Vanessa Sperandio

Copyright © 2009 King-Ting Lim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The emergence of Escherichia coli that produce extended spectrum -lactamases (ESBLs) and are multidrug resistant (MDR) poses antibiotic management problems. Forty-seven E. coli isolates from various public hospitals in Malaysia were studied. All isolates were sensitive to imipenem whereas 36 were MDR (resistant to 2 or more classes of antibiotics). PCR detection using gene-specific primers showed that 87.5% of the ESBL-producing E. coli harbored the gene. Other ESBL-encoding genes detected were , , and . Integron-encoded integrases were detected in 55.3% of isolates, with class 1 integron-encoded intI1 integrase being the majority. Amplification and sequence analysis of the CS region of the integrons showed known antibiotic resistance-encoding gene cassettes of various sizes that were inserted within the respective integrons. Conjugation and transformation experiments indicated that some of the antibiotic resistance genes were likely plasmid-encoded and transmissible. All 47 isolates were subtyped by PFGE and PCR-based fingerprinting using random amplified polymorphic DNA (RAPD), repetitive extragenic palindromes (REPs), and enterobacterial repetitive intergenic consensus (ERIC). These isolates were very diverse and heterogeneous. PFGE, ERIC, and REP-PCR methods were more discriminative than RAPD in subtyping the E. coli isolates.

1. Introduction

Escherichia coli are one of the main bacterial pathogens responsible for nosocomial infections especially in immuno-compromised patients [1]. Extended-spectrum -lactamases (ESBLs) are enzymes produced by Gram-negative bacilli that mediate resistance to penicillin, cephalosporins, and monobactams and are commonly recognized in Enterobacteriaceae and Pseudomonas aeruginosa [2]. Although most ESBLs are mutants of TEM and SHV enzymes, the CTX-M type -lactamases which have become important, originated from -lactamases found in environmental species of the genus Kluyvera, and this enzyme hydrolyzes cefotaxime and cefriaxone but is weakly active against ceftazidime [3, 4]. These enzymes are present worldwide with more than 50 variants [4]. The emergence of ESBL-producers along with multiple resistant isolates poses a serious problem in the hospital setting. The widespread uses of antibiotics coupled with the transmissibility of resistance determinants mediated by plasmids, transposons, and gene cassettes in integrons are factors that contribute to the increase in antibiotic resistance in bacterial pathogens [1].

Rapid and discriminative subtyping methods are essential for determining the epidemiology of isolates in order to design rational control methods. Available subtyping methods for E. coli include PFGE, plasmid profiling, ribotyping and PCR-based typing methods such as arbitrary-primed PCR, repetitive extragenic palindromes (REPs), and enterobacterial repetitive intergenic consensus (ERIC) [5].

A study from Malaysia reported the presence of the ampC gene and SHV-5 ESBL in clinical isolates of E. coli [6]. However, the genotypic characterization of other resistant isolates has not been reported so far. The objectives of this study were to determine the antimicrobial resistance and ESBL profiles of E. coli isolated from 5 public Malaysian hospitals and to determine their genetic diversity using PCR-based fingerprinting techniques and PFGE. The presence of resistance genes and integrons was also determined via PCR, and their transferability was determined by conjugation and transformation.

2. Materials and Methods

2.1. Bacterial Strains

In this retrospective study, 47 nonrepeat E. coli isolates were collected in 2004 from 47 different patients selected randomly from intensive care units of 5 public hospitals located in different parts of Malaysia. The participating hospitals were Kota Bharu Hospital , Sultanah Aminah Hospital , Kuala Lumpur Hospital , Ipoh Hospital and Queen Elizabeth Hospital . The isolates were from tracheal aspirates , urine , body fluids , blood , pus , bile , catheter tips , and unknown They were identified by standard laboratory methods in the respective hospitals. They were stored in cryovials containing Luria-Bertani broth with 50% glycerol (Invitrogen, USA) at 20°C and 85°C.

2.2. Genotyping by RAPD, REP, and ERIC

Crude DNA from the E. coli obtained by direct cell lysate was used for random amplified polymorphic DNA (RAPD) analysis using primers OPAB04 [7] and OPB17 [8] with cycling conditions as previously described (Table 1).

Table 1: Primer sequences and PCR conditions.

Enterobacterial repetitive intergenic consensus (ERIC) analysis was performed using primer ERIC-1R (Operon Biotechnologies GmBH, Germany) while repetitive extragenic palindrome (REP) analysis was carried out using REP oligonucleotides (Operon Biotechnologies GmBH, Germany) as primers previously reported [9] (Table 1).

Each PCR reaction was carried out in a 25  L volume using 1.5 U of Taq DNA polymerase (Promega, Madison, Wis, USA) in the reaction buffer provided by the manufacturer containing 2.5 mM MgCl2, 50  M of each deoxynucleoside triphosphate, 0.3  M of the selected primer and 5  L of DNA template. Aliquots (10  L) of each PCR product were subjected to electrophoresis on 1.5% agarose gel.

2.3. Genotyping by PFGE

PFGE was performed according to previously described protocols [20] with minor variations. Equal volumes of 1% Seakem Gold agarose (Cambrex Bio Science, Rockland, USA) and standardized cell suspension (OD610 = 1.4; approximately 1 108 cfu/mL) were mixed to form agarose plugs, and the bacteria lysed within the plugs with cell lysis buffer (50 mM Tris; 50 mM EDTA (pH 8.0), 1% Sacrosine, 1 mg/mL proteinase K) and incubated at 54°C for 3 hours. Plugs were then washed with sterile deionised water (twice) and TE buffer (4 times), then digested with 12 U of XbaI (Promega, Madison, Wis, USA), and incubated overnight at 37°C. The XbaI-digested DNA was separated on a CHEF-DRIII (BioRad, Hercules, CA, USA) with pulse times of 2.2–54.2 seconds at 200 V for 24 hours, and gels were photographed under UV light after staining with 0.5  g/mL ethidium bromide.

2.4. Fingerprint Pattern Analysis

The banding patterns generated by RAPD, ERIC-PCR, REP-PCR, and PFGE were analyzed using GelCompar II, version 2.5 (Applied Maths, Kortrijk, Belgium). PCR fingerprints and PFGE profiles were assigned arbitrary designation and analyzed by defining a similarity (Dice) coefficient F [21]. Cluster analysis based on the unweighted pair group method with arithmetic averages (UPGMA) with a position tolerance of 0.15 was done using the GelCompar II software.

2.5. Antimicrobial Susceptibility Testing and Screening for ESBL

Eighteen antimicrobial agents were tested by the disk diffusion method in accordance with CLSI guidelines [22]: ampicillin 10  g, piperacillin 100  g, amoxicillin-clavulanic acid 20  g/10  g, cefriaxone 30  g, ceftazidime 30  g, cefepime 30  g, cefoperazone 75  g, aztreonam 30  g, imipenem 10  g, amikacin 30  g, streptomycin 10  g, gentamicin 30  g, kanamycin 30  g, tetracycline 30  g, chloramphenicol 30  g, ciprofloxacin 5  g, trimethoprim-sulfamethoxazole 75  g, and nalidixic acid 30  g (Oxoid Ltd., Basingtoke, Hampshire, England). Isolates were screened for ESBL production by the CLSI disk diffusion method using cefriaxone 30  g, ceftazidime 30  g, and aztreonam 30  g [22]. The double-disk synergy test was performed according to established protocols and results interpreted as described previously [23].

Phenotypic confirmatory test was performed with 30  g ceftazidime, 30/10  g ceftazidime-clavulanic acid (Becton, Diskson & Company, Maryland, USA), 30  g cefotaxime and 30/10  g cefotaxime-clavulanic acid (Becton, Diskson & Company, Maryland, USA) disks on Mueller-Hinton agar. The results were interpreted as described [22]. E. coli isolates ATCC 25922 and ATCC 35218, Klebsiella pneumoniae ATCC 700603, and P. aeruginosa ATCC 27853 were used as controls.

2.6. Detection of ESBL Genes

-lactamase genes (bla TEM , bla SHV , bla CTX-M , bla OXA , bla VEB , bla DHA ) were detected by PCR using reverse and forward primer pairs listed in Table 1. Boiled suspension of bacterial cells was used as DNA template, and cycling parameters were as previously described [1013] with minor modifications (Table 1). Primers 1R, 1, 8F, 8R, 2F, 2R, 9F, and 9R [15] were used for further subgrouping of the bla CTX-M gene into CTX-M groups 1, 2, 8/25, and 9. All amplified products obtained were sequenced to validate their identities.

Two ESBL-producing isolates (EC19 and EC31) were further tested by using primers specific for bla ACT , bla GES , bla VIM , bla PER , and bla FOX genes using conditions as listed in Table 1.

Clinical isolates of E. coli were used as the positive controls for bla TEM , bla SHV , bla CTX-M , and bla OXA genes. No positive controls were available for detection of bla VEB , bla ACT , bla GES , bla VIM , bla PER , bla FOX , and bla DHA genes and subgrouping of CTX-M group amplified 2, 8/25, and 9.

2.7. Detection of Class 1, 2, and 3 Integrons

Class 1, 2, and 3 integrons were detected by PCR using established primers and conditions as listed in Table 1. Selected amplified products were sequenced to corroborate their identities.

2.8. Transfer of Antibiotic Resistance Determinants

Transfer of resistance genes was attempted in broth using nalidixic resistant recipient E. coli JM109 (endA1, recA1, gyrA96, thi, hsdR17 (rk-, ), relA1, supE44, -, (lac-proAB), ( , traD36, proAB, lacI q ZΔZM15). Transconjugants were selected on Luria-Bertani agar supplemented with ampicillin (100  g/mL) plus nalidixic acid (100  g/mL) (Sigma Aldrich, USA).

Transformation experiments were carried out for isolates in which conjugation failed to produce positive results. Plasmid DNA was extracted from ESBL-producing E. coli using the QIAprep Spin Miniprep Kit (QIAGEN, Hilden, Germany) and was transformed by electroporation into electrocompetent E. coli DH10B (F-mcrA (mrr-hsdRMS-mcrBC) 80lacZ lacX74 recA1 endA1 araD139 (ara, leu)7697 galU galK -rpsL nupG tonA). Transformants were selected on Luria-Bertani agar plates containing 100  g/mL ampicillin (Sigma Aldrich, USA).

Size determination of the plasmids from transconjugants and transformants was carried out by digestion with EcoRI or SphI (Promega, Madison, Wis, USA), and the products separated in 0.8% agarose gels at 70 V for 4 hours.

3. Results

3.1. PCR-Based Fingerprinting

Three PCR-based DNA fingerprinting methods were used to subtype the 47 E. coli isolates. ERIC-PCR analysis differentiated the 47 isolates into 45 unique profiles ( –1.0) whereas RAPD using the OPAB04 and OPB17 primers generated 44 and 43 profiles, respectively, ( –1.0 for the OPAB04 primer and –1.0 for the OPB17 primer, see Figures 1(a) and 1(b)). REP-PCR differentiated the 47 isolates into 45 distinct profiles ( –1.0, see Figure 1(c)). All three PCR-based methods were reproducible as identical profiles were obtained in separate experiments using the same set of isolates.

Figure 1: (a) Representative ERIC-PCR profiles for E. coli isolates. Lanes 1, 10, 20: 100 bp DNA ladder, lanes 2–4: EC1-EC3; lanes 5–9: EC17, EC19, EC18, EC30, EC34, lanes 11–18: EC32, EC14, EC41, EC39, EC42, EC22, EC45, EC46; lane 19: negative control. (b) Representative RAPD profiles for E. coli isolates. Lanes 1, 21: 1 kb DNA ladder; lane 2, 20: 100 bp DNA ladder; lanes 3–18: EC5, EC8, EC13, EC15, EC7, EC44, EC12, EC24, EC25, EC29, EC35, EC40, EC26, EC43, EC46, EC47; lane 19: negative control. (c) Representative REP-PCR profiles for E. coli isolates. Lane 1, 21: 1 kb DNA ladder; lane 2, 20: 100 bp DNA ladder; lanes 3–18: EC5, EC8, EC13, EC15, EC7, EC44, EC12, EC24, EC25, EC29, EC35, EC26, EC40, EC43, EC46, EC47; lane 19: negative control. (d) Representative PFGE profiles for E. coli isolates. Lanes 1, 7, 14: Salmonella Braenderup H9812 Standard DNA marker; lanes 2–6: EC4, EC9, EC38, EC36, EC18; lanes 8–13: EC28, EC31, EC40, EC22, EC45, EC46.

Two isolates, EC14 and EC34, from the same hospital but from different wards, yielded identical profiles by all the 3 methods. Two other blood isolates, EC12 and EC24, from 2 different patients in the same ward, were also indistinguishable by their ERIC, REP, and RAPD profiles. ESBL-producing isolates EC4, EC9, and EC20 were clonally related by both RAPD and REP-PCR. Isolates EC4 and EC9 were indistinguishable by RAPD using the OPAB04 primer whereas isolates EC4 and EC20 were indistinguishable by RAPD using the OPB17 primer. However, isolates EC4 and EC9 were in the same cluster (92% similarity) based on their ERIC-PCR profiles.

3.2. PFGE with XbaI-Digested Genomic DNA

XbaI-digested genomic DNA of the 47 E. coli isolates resulted in 44 distinct pulsed-field profiles (PFPs) comprising 12–26 restriction fragments. The 2 E. coli strains that had identical ERIC-PCR, REP-PCR and RAPD profiles (i.e., EC12 and EC24) were similarly indistinguishable by their PFPs with both sharing all 14 restriction fragments.

Two other isolates, EC1 and EC4 which were indistinguishable by PFGE but were distinguishable in their ERIC, RAPD and REP-PCR profiles, had 39%–68% similarities. Similarly, ERIC, RAPD, and REP-PCR differentiated isolates EC37 and EC39 that displayed identical PFPs. Both EC37 and EC39 were isolated from the same hospital. On the other hand, isolates EC14 and EC34 that displayed identical ERIC, RAPD, and REP-PCR profiles could be differentiated by PFGE

3.3. Combined Analysis

A dendrogram based on the combined fingerprints generated by ERIC-PCR, RAPD, REP-PCR, and PFGE was constructed (Figure 2). All the 47 isolates were differentiated into 46 combined subtypes (Table 2). Two isolates, EC12 and EC24, with the combined profile E12R12A11B12X11 were identical in their ERIC, RAPD, REP, and PFGE profiles. Three other isolates (EC4, EC9, and EC20) were grouped within the same cluster and were clonally related (more than 85% similarity). Isolates EC14 and EC34 were also grouped together within the same cluster and were clonally related (more than 94% similarity).

Table 2: Antimicrobial resistance, size of plasmids and ESBL genes detected in the selected donor E. coli isolates, and their respective transconjugants and transformants.
Figure 2: Dendrogram generated using UPGMA based on Dice coefficients of similarity for the clustering of the E. coli combined profile. The dotted blue vertical line indicates 80% similarity level.
3.4. Antimicrobial Susceptibility

The antibiotic resistant rates for the E. coli isolates were as follows: ampicillin 77%, piperacillin 64%, tetracycline 53%, trimethoprim-sulfamethoxazole 43%, cefoperazone and kanamycin 30% each, nalidixic acid 28%, chloramphenicol 26%, ciprofloxacin 23%, gentamicin 21%, amoxicillin-clavulanic acid 17%, cefriaxone ceftazidime and aztreonam 11% each, and amikacin 2%. All 47 isolates were sensitive to imipenem. Majority of the isolates were sensitive to cefepime except EC28, EC34, and EC37 that showed intermediate susceptibility. Among them, 36 isolates (76.5%) were multidrug-resistant. The cephalosporin resistant isolates were also resistant to ampicillin and 71% of them resistant to tetracycline. A large number of isolates that were resistant to aminoglycosides (72%) were also resistant to tetracycline.

Thirty-six (76.5%) isolates were presumptive ESBL producers based on initial screening. Using the double-disk synergy test, only 3 ESBL producing isolates were detected. However, based on the phenotypic confirmatory test, 10 isolates were found to be ESBL producers. All isolates that tested positive for ESBL were also multidrug-resistant.

3.5. Detection of Genes Encoding ESBLs

Established primers were used on the genomic and plasmid DNA of the 47 E. coli isolates for the following ESBL-encoding genes: bla TEM , bla SHV , bla OXA , bla CTX-M , bla DHA , and bla VEB . The bla TEM-1 gene was detected in 35 (74.5%) whereas bla SHV -, bla CTX-M -, and bla OXA -specific amplicons were detected in only 3, 8, and 2 isolates, respectively. Of the 35 bla TEM isolates, 7 also harbored bla CTX-M and 1 had bla SHV . Three ESBL genes were detected in E. coli isolate EC7: bla SHV , bla OXA , and bla CTX-M . bla DHA , and bla VEB were not detected in any of the isolates. All bla TEM , bla SHV , and bla OXA genes were carried on plasmids whereas 6 of the 8 bla CTX-M genes were plasmid-borne. No ESBL-encoding gene was detected in 2 presumptive ESBL-producers, EC19 and EC31. Sequencing of the amplified products indicated complete identity with the respective gene sequences (i.e., bla TEM , bla SHV , bla OXA , and bla CTX-M ) in the NCBI database. Further analysis of the bla TEM sequences indicated that the E. coli isolates harbored the TEM-1 subgroup whereas for bla OXA , the subgroup found in the isolates was OXA-1. In the case of the bla CTX-M gene, DNA sequences analysis indicated that 3 of the 8 isolates detected belonged either to subgroup CTX-M-15 or to subgroup CTX-M-28. However, it was not possible to further subgroup the remaining 5 bla CTX-M genes, as the primers used did not amplify the entire bla CTX-M reading frame. The subsequent use of primers 1R, 1, 8F, 2F, 2R, 8R, 9F, and 9R [15] to further subgroup the 5 bla CTX-M genes could only indicate that they did not belong to subgroups 1, 2, 8/25, and 9. Similarly, we were unable to subgroup the bla SHV genes as the primers used only amplified a portion of the gene and not the entire reading frame.

3.6. Class 1, 2, and 3 Integrons

Forty-seven E. coli isolates were screened for the presence of integrases encoded on class 1, 2, and 3 integrons. The class 1 integron-encoded intI1 integrase gene was detected in 25 isolates while 4 isolates tested positive for class 2-encoded intI2 integrase. One isolate, EC24, was found to harbor both intI1 and intI2. No class 3 integron was detected. Majority of the integrons were found to be plasmid-encoded (16 of the 25 intI1 and 3 of the 4 intI2 detected).

Isolates that were positive for class 1 and 2 integrons were further analyzed for the presence of inserted gene cassettes within the variable region by using the primer pair _CS/ _CS for class 1 integrons and primer pair orfx/attI2 for class 2 integrons. Amplified products of different sizes were obtained from 17 of the 25 intI1-positive isolates and sequencing indicated the presence of 5 different types of known gene cassettes: aadA5-dfrA17, dfrA7, aadA1-aadB-cmlA6, dfrA12-aadA2-orfF and aadA1. Using the attI2/orfX primer pair for intI2-positive isolates resulted in a 2 kb amplified product which, when sequenced, contained the dfrA1-aadA1-sat2 gene cassette. The aadA2, aadA5, and aadB genes encode resistance to aminoglycosides whereas sat2 encode resistance to strepthoricin. Both dfrA12 and dfrA17 encode resistance to trimethoprim and cmlA6 to chloramphenicol. Although trimethoprim and strepthoricin were not used in our study, the presence of gene cassettes encoding resistance to aminoglycosides and chloramphenicol coincided with the resistance profiles of the respective isolates. The majority of the integron-positive isolates (24 of 27) were multidrug-resistant.

3.7. Transfer of Resistance Determinants

Conjugation experiments were carried out for 7 randomly-selected ESBL-producers and transfer of this phenotype to the recipient nalidixic acid-resistant E. coli JM109 was successful in only 3 of the 7 isolates (38%). However, it should be noted that only broth matings were carried out in this study and not filter matings and thus the transmissibility potential for the other 4 isolates could not be fully ascertained. All transconjugants were resistant to ampicillin and piperacillin except for the EC18 which remained susceptible to piperacillin. Streptomycin resistance was cotransferred in the EC46 transconjugant whereas for the EC31 transconjugant, trimethoprim-sulfomethaxazole and cefoperazone resistances were also transferred (Table 2).

Identical EcoRI and SphI restriction profiles were obtained from plasmids extracted from the donor E. coli and their respective transconjugants except for EC31. In this case, based on the restriction profiles obtained, the plasmid extracted from the transconjugant was smaller than the plasmid obtained from the donor EC31 strain (approximately 40 kb from the transconjugant as compared to 90 kb from the donor) although they shared a number of common restriction bands (Table 2). Plasmids extracted from the transconjugants were used to transform electrocompetent E. coli DH10B cells. Plasmids extracted from the resulting ampicillin resistant DH10B transformants showed identical EcoRI restriction profiles with those from their respective transconjugants. The DH10B transformants also displayed identical antibiotic resistance profiles as their respective transconjugants, strongly implying that these antibiotic resistance determinants were plasmid-borne.

Both bla TEM and intI1 were detected on the plasmids extracted from the EC18 and EC46 donor, transconjugants as well as their subsequent transformants indicating that these 2 genes were likely present on the plasmid that was transferred. None of the common ESBL-encoding genes were detected in EC31 although this isolate harbored class 1 integron-encoded intI that was detected from the plasmid in the EC31 transconjugant and transformant suggesting that the transferred plasmid harbored a class 1 integron.

Transformation was carried out for the 4 isolates in which conjugation was not successful and another ESBL-positive randomly chose isolate. Plasmids were extracted from these 5 isolates and electroporated into recipient E. coli DH10B cells. All transformants obtained were resistant to ampicillin, piperacillin, tetracycline, and trimethoprim-sulfamethoxazole. Plasmids extracted from the transformants showed identical EcoRI restriction profiles when compared to their respective donor plasmids except for isolate EC7 in which the plasmid isolated from the transformant was smaller ( 55 kb) when compared to the hospital isolate ( 135 kb) (Table 2). Both bla TEM and intI1 genes were also detected from the plasmids isolated from the donor isolates as well as the transformants except for isolate EC7 and its transformant.

4. Discussion

Genotyping by PCR-based methods and PFGE showed the 47 E. coli clinical isolates to be genetically diverse and heterogeneous. This is expected as the isolates were randomly selected from different hospitals and sources. Similar observations were reported by Mugnaioli et al. [24] and Woodford et al. [16]. We found that ERIC and REP-PCR yielded practically identical results and able to differentiate strains which were indistinguishable by RAPD. Although PCR-based fingerprinting is rapid, it is more susceptible to technical variations than PFGE especially reproducibility. Thus PFGE is considered the better method for subtyping of E. coli, even though it is relatively laborious and time-consuming compared to PCR-based methods.

Isolates EC12 and EC24 were indistinguishable by both PFGE and PCR fingerprints. These two blood isolates were from different patients in the same ward, strongly suggesting a possible nosocomial spread. Interestingly, both isolates harbored plasmids of different sizes with EC12 harboring a plasmid of 50 kb whereas EC24 contained a plasmid of 60 kb. On the other hand, there were isolates that were identical in their PCR fingerprints but were differentiated by their PFGE profiles (e.g., isolates EC14 and EC34) and conversely, isolates that were indistinguishable by PFGE were differentiated by PCR (isolates EC1 and EC4, and EC37 and EC39). This shows that these methods are complementary and a combined analysis would give a finer perspective bearing in mind the drawbacks of each of these methods.

All 47 E. coli isolates analyzed in this study were susceptible to imipenem. This finding is similar to previous reports [16, 25]. Cefepime was equally sensitive at 98% which is a rate higher than the 80% sensitivity reported in Colombia [25] and 70% in China [26].

The resistance rates of chloramphenicol, trimethoprim-sulfomethaxazole, tetracycline, gentamicin, kanamycin, ciprofloxacin and nalidixic acid were 7% to 69% lower compared to a report by Alhaj et al. [27].

The resistance rates of E. coli isolates to ceftazidime (11%) and amoxillin-clavulanic acid (17%) were lower when compared to that from China—28% for ceftazidime and 84% for amoxillin-clavulanic acid [26]. E. coli resistance to amikacin in Malaysia (2% in this study) was still relatively low compared to 27% in Colombia [25] or 22.4% in Israel [28].

Forty E. coli isolates were classified as ESBL producers based on phenotypic or genotypic detection of ESBL: 38 isolates were classified as ESBL producers based on the genotypic detection of ESBL-encoding genes, and 2 others were categorized as ESBL producers based on the double-disk synergy and phenotypic confirmatory tests. However, these two isolates, EC7 and EC31, did not harbor any of the tested ESBL-encoding genes and may instead harbor other genes such as bla TLA , bla IMP , and bla CMY [1, 29] that were not included in our test. Although the double-disk synergy test had been reported to be reliable and easy-to-use, its major disadvantage is that the distance of disk placement for optimal sensitivity has not been standardized [20, 29].

Analysis of the ESBL-encoding genes indicated that the majority of the ESBL-positive isolates harbored TEM-1 (88%) followed by CTX-M (20%), SHV (8%), and finally, OXA (5%). TEM-1 has been reported to be responsible for 90% of ampicillin resistance in E. coli [30]. The bla CTX-M gene is considered the most prevalent ESBL-encoding gene worldwide and is replacing TEM and SHV types as the predominant ESBL in many European countries [31]. The presence of the bla SHV-5 gene in 11 ceftazidime resistant E. coli isolates from one Malaysian teaching hospital has been reported [6]. The specific SHV subtypes could not be confirmed in this study as the primers used only amplified a portion of the bla SHV reading frame.

Analysis of integron-encoded integrases indicated that class 1 integron was the principal integron class in the Malaysian strains. Class 2 integron was in the minority, and no class 3 integron-encoded integrases were detected, a trend that has previously been reported [14, 32]. Four different gene cassettes, namely, the aadA1, dfrA17-aadA5, dfrA12-orfF-aadA2, and aadA1-aadB-cmlA6 were found in the class 1 integron-positive isolates, and these have been previously described in E. coli as well as in other Enterobacteriaceae [15]. All 4 isolates positive for class 2 integron-encoded intI2 harbored the dfrA1-sat2-aadA1 gene cassette which has been reported [1, 33]. Conjugation and transformation experiments indicated that the majority of the integrons and some of the ESBL-encoding genes (in particular bla TEM ) were plasmid-encoded and transmissible. Plasmids that were isolated from the E. coli hospital isolates were estimated to be larger than 50 kb in agreement with the sizes reported previously [34, 35]. In 2 of the 3 successful conjugation experiments, plasmids with identical restriction profiles were isolated from the donor and the transconjugants. In the remaining case, based on the restriction profiles obtained, the plasmid that was isolated from the transconjugant was about 50 kb smaller than the donor EC31 strain ( 90 kb), indicating either that the donor strain harbored more than a single type of plasmid and that only the plasmid of about 40 kb was transferred, or that only a 40 kb portion of the original plasmid was successfully transferred by conjugation. The latter appeared to be a stronger possibility as separation of undigested plasmid DNA extracted from the parental EC31 strain seemed to indicate the presence of a single plasmid. Similar observations were also noted for the transformation experiments. Further characterization of these plasmids is clearly needed and is the subject of our on-going investigations. Nevertheless, our results indicate that most of the ESBL-encoding genes especially bla TEM are carried on plasmids which are transmissible suggesting that the spread of ESBL and other antibiotic resistance determinants is likely to be plasmid-mediated in agreement with the conclusions made by other reports [36, 37] that plasmids are one of the main vehicles for spread of antibiotic resistance genes. This may have led to the high prevalence of ESBL-producers and multidrug resistance among E. coli hospital isolates in Malaysia.


This work was funded by grants from the Malaysian Ministry of Science, Technology and Innovation (MOSTI), the Malaysian Toray Science Foundation, and University of Malaya. The authors thank MOSTI for providing an NSF scholarship to LKT. They thank Ms. Nurahan Maning, Zubaidah Abdul Wahab, Noraini Ismail, Eng Am Tan, and Dr. Ganeswrie Balan for providing the clinical isolates. Part of this study was presented as a poster at the 6th ISAAR, Raffles City, Singapore, in 2007.


  1. H. Y. Kang, Y. S. Jeong, J. Y. Oh et al., “Characterization of antimicrobial resistance and class 1 integrons found in Escherichia coli isolates from humans and animals in Korea,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 5, pp. 639–644, 2005. View at Publisher · View at Google Scholar
  2. F. C. Tenover, P. M. Raney, P. P. Williams et al., “Evaluation of the NCCLS extended-spectrum ß-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE,” Journal of Clinical Microbiology, vol. 41, no. 7, pp. 3142–3146, 2003. View at Publisher · View at Google Scholar
  3. R. Bonnet, “Growing group of extended-spectrum β-lactamases: the CTX-M enzymes,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 1, pp. 1–14, 2004. View at Publisher · View at Google Scholar
  4. F. Perez, A. Endimiani, K. M. Hujer, and R. A. Bonomo, “The continuing challenge of ESBLs,” Current Opinion in Pharmacology, vol. 7, no. 5, pp. 459–469, 2007. View at Publisher · View at Google Scholar
  5. L. G. Dos Anjos Borges, V. D. Vechia, and G. Corcao, “Characterisation and genetic diversity via REP-PCR of Escherichia coli isolates from polluted waters in southern Brazil,” FEMS Microbiology Ecology, vol. 45, no. 2, pp. 173–180, 2003. View at Publisher · View at Google Scholar
  6. G. Subramaniam, S. Palasubramaniam, and P. Navaratnam, “SHV-5 extended-spectrum β-lactamases in clinical isolates of Escherichia coli in Malaysia,” Indian Journal of Medical Microbiology, vol. 24, no. 3, pp. 205–207, 2006. View at Google Scholar
  7. R. Latha, T. S. Suryanarayanan, and M. S. Swaminathan, “Genetic diversity in Acremonium endophytes isolated from warm-season grasses as revealed by RAPD markers,” Journal of Plant Biochemistry and Biotechnology, vol. 13, no. 1, pp. 39–42, 2004. View at Google Scholar
  8. S. Chatellier, M. Gottschalk, R. Higgins, R. Brousseau, and J. Harel, “Relatedness of Streptococcus suis serotype 2 isolates from different geographic origins as evaluated by molecular fingerprinting and phenotyping,” Journal of Clinical Microbiology, vol. 37, no. 2, pp. 362–366, 1999. View at Google Scholar
  9. M. M. Navia, L. Capitano, J. Ruiz et al., “Typing and characterization of mechanisms of resistance of Shigella spp. isolated from feces of children under 5 years of age from Ifakara, Tanzania,” Journal of Clinical Microbiology, vol. 37, no. 10, pp. 3113–3117, 1999. View at Google Scholar
  10. A. Oliver, L. M. Weigel, J. K. Rasheed, J. E. McGowan Jr., P. Raney, and F. C. Tenover, “Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 12, pp. 3829–3836, 2002. View at Publisher · View at Google Scholar
  11. L. Pagani, E. Dell'Amico, R. Migliavacca et al., “Multiple CTX-M-type extended-spectrum ß-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northern Italy,” Journal of Clinical Microbiology, vol. 41, no. 9, pp. 4264–4269, 2003. View at Publisher · View at Google Scholar
  12. H. Pai, C.-I. Kang, J.-H. Byeon et al., “Epidemiology and clinical features of bloodstream infections caused by AmpC-type-ß-lactamase-producing Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 10, pp. 3720–3728, 2004. View at Publisher · View at Google Scholar
  13. X. Jiang, Z. Zhang, M. Li, D. Zhou, F. Ruan, and Y. Lu, “Detection of extended-spectrum β-lactamases in clinical isolates of Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 9, pp. 2990–2995, 2006. View at Publisher · View at Google Scholar
  14. E. Machado, R. Cantón, F. Baquero et al., “Integron content of extended-spectrum-ß-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 5, pp. 1823–1829, 2005. View at Publisher · View at Google Scholar
  15. V. M. Ensor, D. M. Livermore, and P. M. Hawkey, “A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum β-lactamases,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 3, pp. 387–395, 2007. View at Publisher · View at Google Scholar
  16. N. Woodford, M. E. Ward, M. E. Kaufmann et al., “Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum ß-lactamases in the UK,” Journal of Antimicrobial Chemotherapy, vol. 54, no. 4, pp. 735–743, 2004. View at Publisher · View at Google Scholar
  17. P. Giakkoupi, A. Xanthaki, M. Kanelopoulo et al., “VIM-1 metallo-ß-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals,” Journal of Clinical Microbiology, vol. 41, no. 8, pp. 3893–3896, 2003. View at Publisher · View at Google Scholar
  18. P. E. Coudron, N. D. Hanson, and M. W. Climo, “Occurrence of extended-spectrum and ampC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases,” Journal of Clinical Microbiology, vol. 41, no. 2, pp. 772–777, 2003. View at Publisher · View at Google Scholar
  19. F. J. De Bruijn, “Use of repetitive (repetitive extragenic palindromic and enterobacterial repetitive intergeneric consensus) sequences and the polymerase chain reaction to fingerprint the genomes of Rhizobium meliloti isolates and other soil bacteria,” Applied and Environmental Microbiology, vol. 58, no. 7, pp. 2180–2187, 1992. View at Google Scholar
  20. S. Tofteland, B. Haldorsen, K. H. Dahl et al., “Effects of phenotype and genotype on methods for detection of extended-spectrum-ß-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway,” Journal of Clinical Microbiology, vol. 45, no. 1, pp. 199–205, 2007. View at Publisher · View at Google Scholar
  21. K. L. Thong, K. S. Lai, S. D. Puthucheary, Y. T. Koh, N. Ahmad, and R. M. Yassin, “Subtyping of Salmonella enterica serovar Muenchen by pulsed-field gel electrophoresis, plasmid profiling and antimicrobial susceptibility testing,” Malaysian Journal of Science, vol. 26, no. 2, pp. 1–13, 2007. View at Google Scholar
  22. Clinical and Laboratory Standards Institute, “Performance standards for antimicrobial susceptibility testing,” Fifteenth informational supplement. Approved standard MS100-S16. Wayne, PA: CLSI; 2006.
  23. V. Jarlier, M. H. Nicolas, G. Fournier, and A. Philippon, “Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns,” Reviews of Infectious Diseases, vol. 10, no. 4, pp. 867–878, 1988. View at Google Scholar
  24. C. Mugnaioli, F. Luzzaro, F. De Luca et al., “CTX-M-type extended-spectrum ß-lactamases in Italy: molecular epidemiology of an emerging countrywide problem,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 8, pp. 2700–2706, 2006. View at Publisher · View at Google Scholar
  25. M. V. Villegas, A. Correa, F. Perez, M. C. Miranda, T. Zuluaga, and J. P. Quinn, “Prevalence and characterization of extended-spectrum β-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals,” Diagnostic Microbiology and Infectious Disease, vol. 49, no. 3, pp. 217–222, 2004. View at Publisher · View at Google Scholar
  26. Y. Yu, S. Ji, Y. Chen et al., “Resistance of strains producing extended-spectrum ß-lactamases and genotype distribution in China,” Journal of Infection, vol. 54, no. 1, pp. 53–57, 2007. View at Publisher · View at Google Scholar
  27. N. Alhaj, N. S. Mariana, A. R. Raha, and Z. Ishak, “Prevalence of antibiotic resistance among Escherichia coli from different sources in Malaysia,” Research Journal of Pharmacology, vol. 1, pp. 44–49, 2007. View at Google Scholar
  28. R. Colodner, Z. Samra, N. Keller et al., “First national surveillance of susceptibility of extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel,” Diagnostic Microbiology and Infectious Disease, vol. 57, no. 2, pp. 201–205, 2007. View at Publisher · View at Google Scholar
  29. P. A. Bradford, “Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat,” Clinical Microbiology Reviews, vol. 14, no. 4, pp. 933–951, 2001. View at Publisher · View at Google Scholar
  30. D. M. Livermore, “β-lactamases in laboratory and clinical resistance,” Clinical Microbiology Reviews, vol. 8, no. 4, pp. 557–584, 1995. View at Google Scholar
  31. D. M. Livermore, R. Canton, M. Gniadkowski et al., “CTX-M: changing the face of ESBLs in Europe,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 2, pp. 165–174, 2007. View at Publisher · View at Google Scholar
  32. A. van Essen-Zandbergen, H. Smith, K. Veldman, and D. Mevius, “Occurrence and characteristics of class 1, 2 and 3 integrons in Escherichia coli, Salmonella and Campylobacter spp. in the Netherlands,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 746–750, 2007. View at Publisher · View at Google Scholar
  33. I. S. Henriques, F. Fonseca, A. Alves, M. J. Saavedra, and A. Correia, “Occurrence and diversity of integrons and β-lactamase genes among ampicillin-resistant isolates from estuarine waters,” Research in Microbiology, vol. 157, no. 10, pp. 938–947, 2006. View at Publisher · View at Google Scholar
  34. C. Eckert, V. Gautier, M. Saladin-Allard et al., “Dissemination of CTX-M-type ß-lactamases among clinical isolates of Enterobacteriaceae in Paris, France,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 4, pp. 1249–1255, 2004. View at Publisher · View at Google Scholar
  35. S. Lavilla, J. J. González-López, M. Sabaté et al., “Prevalence of qnr genes among extended-spectrum ß-lactamase-producing enterobacterial isolates in Barcelona, Spain,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 2, pp. 291–295, 2008. View at Publisher · View at Google Scholar
  36. C.-R. Li, Y. Li, and P.-A. Zhang, “Dissemination and spread of CTX-M extended-spectrum β-lactamases among clinical isolates of Klebsiella pneumoniae in central China,” International Journal of Antimicrobial Agents, vol. 22, no. 5, pp. 521–525, 2003. View at Publisher · View at Google Scholar
  37. D. Sompolinsky, Y. Nitzan, S. Tetry et al., “Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 1, pp. 119–122, 2005. View at Publisher · View at Google Scholar